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Background: The BTB-KELCH protein Gigaxonin plays key roles in sustaining neuron survival and cytoskeleton
architecture. Indeed, recessive mutations in the Gigaxonin-encoding gene cause Giant Axonal Neuropathy (GAN), a
severe neurodegenerative disorder characterized by a wide disorganization of the Intermediate Filament network.
Growing evidences suggest that GAN is a continuum with the peripheral neuropathy Charcot-Marie-Tooth diseases
type 2 (CMT2). Sharing similar sensory-motor alterations and aggregation of Neurofilaments, few reports have
revealed that GAN and some CMT2 forms can be misdiagnosed on clinical and histopathological examination. The
goal of this study is to propose a new differential diagnostic test for GAN/CMT2. Moreover, we aim at identifying
the mechanisms causing the loss-of-function of Gigaxonin, which has been proposed to bind CUL3 and substrates
as part of an E3 ligase complex.
Results: We establish that determining Gigaxonin level constitutes a very valuable diagnostic test in discriminating
new GAN cases from clinically related inherited neuropathies. Indeed, in a set of seven new families presenting a
neuropathy resembling GAN/CMT2, only five exhibiting a reduced Gigaxonin abundance have been subsequently
genetically linked to GAN. Generating the homology modeling of Gigaxonin, we suggest that disease mutations
would lead to a range of defects in Gigaxonin stability, impairing its homodimerization, BTB or KELCH domain
folding, or CUL3 and substrate binding. We further demonstrate that regardless of the mutations or the severity of
the disease, Gigaxonin abundance is severely reduced in all GAN patients due to both mRNA and protein instability
mechanisms.
Conclusions: In this study, we developed a new penetrant and specific test to diagnose GAN among a set of
individuals exhibiting CMT2 of unknown etiology to suggest that the prevalence of GAN is probably under-evaluated
among peripheral neuropathies. We propose to use this new test in concert with the clinical examination and prior to
the systematic screening of GAN mutations that has shown strong limitations for large deletions. Combining the
generation of the structural modeling of Gigaxonin to an analysis of Gigaxonin transcripts and proteins in patients, we
provide the first evidences of the instability of this E3 ligase adaptor in disease.
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Gigaxonin is a BTB-KELCH protein that plays a central
role in sustaining neuron integrity and cytoskeleton
architecture. Indeed, recessive mutations in the Gigaxonin-
encoding gene are responsible for a devastating neuro-
degenerative disorder in human, called Giant Axonal
Neuropathy (GAN [MIM 256850]) [1], that leads to a
wide deterioration of the nervous system and provokes
a massive disorganization of the Intermediate Filament
(IF) cytoskeleton.
Diagnosed early in infancy, the disease first touches
the peripheral nervous system, altering both the motor
and sensory tracts in teens, and closely resembles to the
most common inherited peripheral neuropathy called
Charcot-Marie-Tooth (CMT) diseases. Thus, patients
exhibit weakness and severe wasting of the four limbs
predominating in distal segments, sensory and motor
loss, and reduced deep tendon reflexes. Symptoms
evolve towards areflexia, loss of the deep and superficial
sensitivity and loss of ambulation. Subsequently, the dis-
ease targets the central nervous system, leading to a
wide range of symptoms encompassing ataxia, nystag-
mus, dysarthria and intellectual disability [2,3]. Fatal in
young adults, GAN is a progressive neurodegenerative
disorder of axonal type. Although few milder cases of
the disease with later onset, absence of central nervous
system impairment, or longer survival have been de-
scribed, GAN invariably causes the massive collapse of
IFs in a variety of tissues, including Neurofilaments
(NFs) in distended or “giant” axons in nerve biopsy [2,3].
Up to recently, NF aggregation in giant axons consti-
tuted a powerful histological test towards the diagnosis
of GAN, which is now compromised by similar histo-
pathological findings in several forms of CMTs [4,5].
While NF aggregation has been reported in many neuro-
degenerative disorders, including Alzheimer’s, Parkinson’s
diseases and Amyotrophic Lateral Sclerosis, possibly as a
results of neuron injury, the disorganization of all classes
of IFs is unique to GAN and supports a crucial role of
Gigaxonin in sustaining cytoskeleton architecture [6]. In
addition to neuronal IF defects, GAN patients display ag-
gregation of GFAP, desmin, keratin and vimentin. In GAN
patient-derived primary fibroblasts, vimentin aggregation
has been shown to be reversible, conditional, and inde-
pendent of microtubule overall stability [7,8]. The central
role of Gigaxonin in regulating IFs has been confirmed in
GAN mouse models, although these only exhibit mild
motor and sensory deficits with no signs of robust neuro-
degeneration [9,10]. Indeed, Gigaxonin-depleted mice
display a massive aggregation, spatial disorganization and
increased abundance of several IF proteins throughout the
central and peripheral nervous system [9,10].
How this low abundance BTB-KELCH protein [8],
preferentially expressed throughout the nervous systemand during development [10], controls neuron survival and
IF architecture remains unknown. One plausible hypoth-
esis is that this would be mediated by the Ubiquitin Protea-
some System (UPS) pathway. Indeed, BTB-containing
proteins, including Gigaxonin have been identified as the
substrate adaptors of Cul3-E3 ubiquitin ligases, mediating
the addition of ubiquitin chains onto their targets prior to
their degradation by the proteaseome [11-13]. Interacting
with the E3 ligase complex to its N-terminal BTB domain,
Gigaxonin is thought to promote the Ubiquitin tagging of
the substrates through interaction with its C-terminal
KELCH domain. Although Gigaxonin has been shown in
cells to participate in regulating the abundance of three
regulators of microtubules, the E3 ligase activity of Gigaxo-
nin remains to be fully established. A first step towards this
goal has been recently reached, in a study revealing that
the overexpression of Gigaxonin induces the degradation
of several IF proteins, including vimentin in primary fibro-
blasts and that this clearance involves the proteasome [14].
To better understand the disease mechanisms in GAN
and provide a specific diagnostic tool able to discrimin-
ate GAN from closely related CMTs, we combine here a
study on Gigaxonin abundance and stability in disease
and a structural modeling of Gigaxonin to a prognostic
study on new patients presenting a sensorimotor neur-
opathy of unknown etiology. We establish that in GAN
patients, mutant Gigaxonin levels are greatly reduced in
abundance. The quantification of Gigaxonin mRNA re-
veals nonsense mRNA decay as one of the disease mecha-
nisms in GAN. In addition, the modelization of Gigaxonin
structure allows us to map GAN mutations and predict a
general destabilization of disease-associated mutants, which
is further confirmed by reduced half-lives of mutant Gigaxo-
nins. Finally, we establish that our immunodetection of
Gigaxonin constitutes a robust, penetrant and specific new
diagnostic test for GAN, circumventing the limitations of
gene sequencing and the clinical and histopathological over-
lap between GAN and the frequent forms of axonal CMTs.
Materials and methods
Preparation of lymphoblast cell lines from patients
Blood samples were collected from patients with written
informed consents and under the agreement n° DC-
2010-1191 of the Bioethic comittee of the Ministère de
l’Enseignement Supérieur et de la Recherche. Numbering
of previously reported GAN patients matches publications
[1,15] for F1-F18 families, and [16] for family F25. New
families included in the study (F23, 24, 26–30) were
addressed to banque d’ADN et de Cellules de Généthon
(Evry, France) for the generation of immortalized cell lines.
Immunoblotting
Cell lines, expanded in RPMI 20% FBS, 1% P/S and
2 mM Glutamine (Invitrogen), were lysed and processed
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antibodies are: Gig A (1:150) [8], DM1α-tubulin from
Merck Millipore n°CP06 (1:10000); GAPDH from Ambion
n°4300 (1:4000). Quantification was performed on 3–5
independant experiments with Image Lab (Biorad) after
normalization with Tubulin or GAPDH. Statistical analysis
was performed using Prism GraphPad.
Genetic analysis
All coding exons and flanking intron sequences of the
GAN gene were Sanger sequenced using primers de-
scribed in [1], the Big Dye Terminator v3.1 sequencing
kit and analyzed on an ABI3130 Genetic Analyzer
(Applied Biosystems, USA). The reference sequence used
for GAN was the NM_022041.2. Variants were compared
to the known public databases (dbSNP, 1000 genomes),
the Inherited Peripheral Neuropathies Mutation Database
(IPNMDB; http://www.molgen.ua.ac.be/CMTmutations/
default.cfm) and Human Gene Mutation Database (HGMD)
to exclude polymporphisms in the normal population.
Genomic rearrangement on the GAN gene was analyzed
on proband and family genomic DNA by High-resolution
custom NimbleGen 135 k CGH microarray (probe spacing
of 75 bp for exons and 200 bp for the introns) versus
reference DNA (Kreatech, Amsterdam, The Nederlands).
The array also included a genomic backbone probe set
with an average probe spacing of 30 kb. DNA samples
were labeled (test with Cy3 and reference with Cy5) and
co-hybridised to the custom microarray in accordance
with the manufacturer’s instructions (NimbleGen Arrays
User’s Guide: CGH and CGH/LOH Arrays v9.1, Roche
NimbleGen, Madison, WI USA). The microarray was
washed and then scanned on an Axon GenePix 4400A
Scanner using GenePix Pro 7 software (Molecular De-
vices, Sunnyvale, CA, USA). Raw data was normalized,
LOESS correction applied and the data ratios calculated
using DEVA v1.01 Software (Roche NimbleGen). The nor-
malized data was processed using Infoquant Fusion v6.0
software (Infoquant, London, UK) with analysis call set-
tings of 3 consecutive probes +/− 0.4 Cy3/Cy5 ratios. The
arrays were used on affected and unaffected family indi-
viduals as well as normal controls.
Quantitative RT-PCR (qRT-PCR)
Total RNA from patients and control cell lines was iso-
lated using the RNeasy MicroKit (Qiagen) according to
the supplier’s recommendations. For each sample, 1 μg
of RNA was used for reverse transcription with oligodT
primers and SuperScriptIII (Invitrogen). SYBR green
quantitative real-time PCR was performed with LightCy-
cler 480 SYBR Green I Master (Roche) in a two-step cyc-
ling protocol on 100 ng of cDNA, using GAN-exon9-11
specific primers (GGGTAGCGAGATGGTAACTTG and
CGGATGGAAGGAGTGGTTTAG) and HPRT1 quantitectprimers (Qiagen). Carrying a deletion in the GAN exons 10
to 11, F24 mRNA level was determined by another set
of primers, i.e. GAN-exon4-5 (QT00018774, Qiagen),
together with appropriate positive and negative con-
trols. The relative abundance of the patient’s mRNA
was expressed as the fold change to the controls
mRNAs. Fold changes were measured as the ratio of
the ΔΔCT of each patient to the ΔΔCT of the controls
after normalization with HPRT1. Three independent
RT-PCR were performed in triplicate for each sample.
Accordingly to the manufacturer’s instructions, only
fold changes exceeding a value of 2 are considered sig-
nificantly different.
Statistical analysis
The student’s t-Test was used to determine statistical
significance. Error bars represent standard deviation and
p values are reported in the Figure legends.
Structural modeling
The structural model of the BTB-BACK domain Gigaxo-
nin bound to the N-terminal domain of CUL3 was gen-
erated as follows. Residues 8–128 were used from the
crystal structure of the BTB domain of Gigaxonin, which
also included a partial model for the BACK domain
(3HVE.pdb, [17]). A complete model for the BACK do-
main (residues 129–256) was obtained from the Phyre
homology modeling server (http://www.sbg.bio.ic.ac.uk/
phyre2/) based on the crystal structure of human KLHL11
(3I3N.pdb) [18]. The BTB domain from Gigaxonin was
superimposed on that from SPOP in complex with the N-
terminal domain from CUL3 (4EOZ.pdb) to add this por-
tion of CUL3 to the model [19]. The KELCH domain of
Gigaxonin (residues 273–577) was modeled with the crys-
tal structure of the KELCH domain of the BTB-BACK-
KELCH protein Keap1, using the Phyre server with 100%
confidence for the fold and based on 1X2R.pdb (27% se-
quence identity) [20,21].
Pulse chase assay
COS cells were transfected by plasmids expressing hu-
man wild type or mutated Gigaxonin tagged with a N-
terminal Flag sequence, using Fugene 6 transfection
(Promega). R138H, L309R, R477X and R15S correspond
to mutations of families F13, F1, F16 and F2, respect-
ively. WT, N-ter and C-ter correspond to the Full-length
Gigaxonin, the BTB domain (residues 1 to 223) and the
KELCH domain (residues 141 to 597), respectively.
24 hours post transfection, cells were washed twice with
PBS, incubated in methionine- and cysteine-free DMEM
(Sigma) supplemented with 10% FBS and 1% P/S for 1 h
before labeling with 100 μCi of S35-methionine/cysteine
(Perkin Elmer) for 45 min. Cells were subsequently
washed twice with PBS and incubated with normal
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Cells were washed with PBS and collected by centrifu-
gation at the beginning of the chase period (0 h) and at
2, 4, 6, 9, 24 hours. Protein extracts were lysed as previ-
ously described for lymphoblast cell lines and immuno-
precipitation was performed on 60 μg of total proteins
using anti Flag antibody (Flag-M2, sigma) and G-protein
(Dynabeads, Fisher scientific). Immunoprecipates were re-
covered in Laemmi buffer and loaded on two identical gels
for autoradiography and immunoblotting (for internal
control). Because immunoblotting of Gigaxonin (using
either the Flag-M2 or the mouse Gigaxonin antibody
(GigA, [8]) hampered the detection of several mutants/
truncated Gigaxonin due to cross reaction with mouse
IgG, we used the supernatents recovered after the incu-
bation of the Gigaxonin-Antibody complex with the G-
protein as the best internal control, using tubulin (DM1α,
1:10000). Three independent labeling-immunoprecipitation
experiments were performed per condition. All quanti-
fications were performed with Image Lab (Biorad) after
normalization with Tubulin. Half-lives were determined
with Prism (Non linear regression).
Results
Decreased abundance of GAN-linked Gigaxonin
Inherited through a recessive mode of inheritance, GAN
is suspected to result from a Gigaxonin loss of function
mechanism. We previously showed a dramatic decrease
in the abundance of mutant Gigaxonin in few GAN pa-
tients using an immunodetection method on immortal-
ized lymphoblast cell lines [8]. To further confirm this
finding on a larger group of patients and determine the
levels of residual mutated Gigaxonin, we quantified the
abundance of Gigaxonin in all GAN patients for which
immortalized lymphoblast cell lines have been derived
and mutations identified (Figure 1). Those include eight
severely affected patients and two mild cases (R15S and
R138H mutations, corresponding to family F2 and F13
in Figure 1A). Univocally, all mutated Gigaxonins, in-
cluding severe but also mild cases were considerably less
abundant than wild type proteins (Figure 1B). Thus, the
levels of mutant Gigaxonin ranges from [0,73 to 36,6]% of
the wild type counterparts, with a mean value of 13,1 ± 5,7
using normalization with tubulin, and a [0,6-37,6]% range
with a mean value of 14,2 ± 10,9 with GAPDH (Figure 1C).
In an attempt to determine whether heterozygous com-
pounds, carrying one wild type Gigaxonin in addition to
one mutated form may exhibit a dose effect in protein
level, we quantified its abundance in patient’s relatives:
unaffected brother of patient F6 and both parents of
patient F11 (Figure 1B, C). Very interestingly, the level
of Gigaxonin in heterozygous individuals ranges from
[35,2-59,9] or [36,3-63,4]% of wild type Gigaxonin using
tubulin or GAPDH normalizators, respectively. Whereasthe mean values of 47,7 ± 14,2 or 53,0 ± 14,6 represent half
of the abundance of healthy individual (carrying 100% of
wild type proteins), this is not statistically significant,
probably due to the intra-individual (as seen for mother of
F11) and inter-individual variability between control sam-
ples. Therefore, we conclude that when mutated in both
alleles, Gigaxonin is greatly reduced in abundance by
85,8% in average and by 99,3% in the most extreme case,
but that additional control and heterozygous individuals
should be tested to convincingly discriminate the latter
from healthy individuals.
Gigaxonin abundance discriminates GAN from closely
related CMT diseases
To assess whether the determination of Gigaxonin abun-
dance could contribute to diagnose GAN, we included
in the study seven new patients presenting a sensori-
motor axonal neuropathy resembling GAN/CMT2 with
unknown genetic etiology (Table 1). Some patients have
simultaneously been evaluated clinically [22].
Among the seven new patients, five of them, namely
patients F23, F24, F26, F28 and F30 present an early
(<4 years) onset progressive neuropathy indicative of the
typical severe form of GAN. As revealed by the reduction
of nerve conduction velocities, they exhibit an axonal
motor and sensory neuropathy with muscle weakness/
tone, areflexia that evolves to the loss of ambulation and
of the deep and superficial sensitivity during childhood.
All patients subsequently develop central nervous sys-
tem impairment encompassing nystagmus, dysarthria
and ataxia. Concomitant with these clinical signs, GAN
has been shown to induce a wide aggregation of the
cytoskeletal IF network both in and out-side the ner-
vous system, and severely affected patients F23, F24,
F26, F28 and F30 all exhibit altered keratins (kinky
hair) and aggregating NFs in enlarged axons (Table 1).
Two additional patients (F27 and F29) present a neur-
opathy differing from the GAN typical form, with ± late
onset, mild central nervous system impairment, ex-
tended survival but with the presence of giant axons and
NF aggregation that may suggest a milder form of GAN
or another related sensori-motor neuropathy called type
2 Charcot-Marie-tooth (CMT) disease. Indeed, we previ-
ously identified two moderate forms of the disease with
very slow progression, no central nervous impairment
and extended survival (F2 in the present study, carrying
a R15S mutation), or with a late onset at 10 years of age,
slow evolution with no central system involvement for
patient F13 (with a R138H mutation).
The quantification of Gigaxonin in patients suspected
of bearing a GAN severe (F23, F24, F26 and F30) and
mild (F27) forms revealed a considerable diminution of
abundance using both normalization methods and that
is comprised in the range established for GAN patients
AB
C
Figure 1 Decreased abundance of disease-associated Gigaxonin. A Schematic representation of Gigaxonin and the corresponding known
mutations in GAN patients. The N-terminal BTB and C-terminal KELCH domains are represented in blue. Lymphoblast cell lines derived from GAN
patients are numbered F1-F25 and their respective mutations are mapped on Gigaxonin. All patients are severely affected by the disease with the
exception of patients F2 and F13, who are mild cases reported previously. B Abundance of Gigaxonin, as revealed by immunoblotting using
the GigA antibody [8]. Cost and c1-c3 correspond to ectopic Flag-tagged Gigaxonin expressed in COS cells and to unrelated control individuals,
respectively. (A), (B), (F) and (M) stand for Affected, non-affected Brother, Father and Mother, respectively. A1 and A2 are two affected children from the
same family. Please note that immunoblottings of patients F18 and F25 are shown in Figure 2A. C Quantification of Gigaxonin in GAN patients and
their relatives. Left: Percentage of Gigaxonin for each individual in comparison to wild type Gigaxonin, as the average of 3–5 independent experiments,
after normalization with tubulin and GAPDH. Right: Mean abundance of Gigaxonin in patients and heterozygous individuals, as measured by the
percentage in comparison to wild type Gigaxonin. (T-test, *, p < 0,05; **, p < 0,01, ***, p < 0,001 and ***, p < 0,0001; error bars represent standard deviation).
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levels reach 25,7 ± 14,8% of the wild type Gigaxonin for
patients F23; 16,9 ± 15,4% for patient F26; 21,3 ± 12,3%
for patient F27 and no detectable Gigaxonin could be
detected for patient F24 and F30 (Figure 2A, left panels).
Gigaxonin levels were compared to the mean abundance
of wild type Gigaxonins and mutated Gigaxonins in
known GAN cases (Figure 2, left and right panels, re-
spectively). This analysis showed that all patients have
Gigaxonin levels that differ from wild type but not from
mutated Gigaxonins (Figure 2B), suggesting that theyare genetically linked to GAN. Testing relatives of pa-
tient F24 revealed that only the mother and sister S1
show a different abundance in comparison to control in-
dividuals, therefore suggesting that, as the mother, this
sister may carry one mutated allele, whereas the other
sister may not.
Surprisingly, patient F28 who shows a severe clinical
presentation similar to GAN presents level of Gigaxonin
that differ both from the range of normal Gigaxonin and
mutated Gigaxonin (Figure 2B, left and right panels,
respectively). As for the atypical patient F29, our
Table 1 Phenotypic data of patients
F23 F24 F26 F27 F28 F29 F30
Country of origin India USA USA New Zealand Northern Europe Portugal North Africa
Consanguinity - - na - - Same village 1 st
Gender F F M M F F F
Onset (year) 4 2,5 2 3 2 11 4
Present age 10 9 10 22 7 38 20*
Muscle weakness/tone + + + + + + +
Reduced MNCVa + + + + na + +
Loss of independence (year) or 8 3 3 10 na - na
Total loss of ambulation (year) sa sa 8 18 7 sa 8
Reduction of sensibilityb S, D S, D S, D S, D S, D S, D S, D
Areflexia (lower limbs) + + + + - + +
Visionc O, N N O, N N N Normal N
Dysarthria + + + - + - +
Ataxia + + + - + - +
Kinky hairs + + + - + - +
Giant axon & NF aggregation + + + ni ni + +
Suspicion of GAN Severe Severe Severe Mild Severe Mild Severe
GAN mutation c.724C > T c.10-11del c.146C > A c.[971C > T]; [1391G > A] - - C.994G > A
(Figure 2) R242X A49E A324V/C464Y G332R
*Deceased; na, not available; sa, still ambulant; ni, not investigated; −, absence.
1st degree of consanguinity means that parents are first cousins.
aMNCV, motor nerve conduction velocity; bS: Superficial sensitivity (light, touch temperature…); D: deep sensitivity (vibration, space…); cO: optic atrophy;
N: nystagmus.
The clinical presentation of patients F23-F27 is further detailed in Roth et al., [22].
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Gigaxonin that could reflect an inter-individual variation
of wild type Gigaxonin, as suggested earlier (Figure 1).
This assumption was reinforced by the fact that the
healthy mother of patient F28 expresses the same amount
of Gigaxonin than her affected child: respectively 71,1 ±
16% versus 63,3 ± 17,5 using tubulin noralization and
109,7 ± 25,1% versus 91,5 ± 19,1 for GAPDH.
To determine whether the decreased abundance of
Gigaxonin found in some patients can be corroborated
by genetic alteration in the GAN gene, a systematic
screening for point mutations and genomic rearrange-
ment was performed in the GAN locus. This analysis re-
vealed that all patients with reduced Gigaxonin level
below the 37,6% maximum level established for known
GAN cases (from Figure 1), carry a mutation in the
GAN gene (Figure 2C). More specifically, Gigaxonin dis-
plays a premature stop codon in amino acid position
242 (R242X) on both alleles for patient F23; a large
homozygous deletion encompassing exon 10 and 11 in
patient F24, the exact deletion is from chr16: 81,402,224
to 81,411,392; a A49E missense mutation at homozygous
state for patient F26, a compound heterozygous muta-
tions A324V/C464Y for patient F27 and a homozygous
G332R for patient F30 (Figure 2C-F). Conversely, whenGigaxonin levels were not compatible with our GAN
known range (as for patient F28 and F29), neither point
mutation nor chromosomal rearrangement could be re-
vealed in the GAN locus. It is interesting to note that
the CGH analysis revealed that Sister S1 of patient F24,
suspected from her Gigaxonin level to be heterozygous
carrier displays indeed this large deletion on one allele,
whereas sister 2 with normal Gigaxonin level does not
carry any deletion. Thus, our study provides evidences that
abundance of Gigaxonin is not only univocally consider-
ably diminished in all GAN patients reported so far, but
that its quantification constitutes an essential tool to dis-
criminate GAN from other hereditary polyneuropathies.
Activation of non sense mediated mRNA decay in GAN
To determine whether the decreased abundance of GAN-
linked Gigaxonins results from defects in mRNA and/or
protein processing, we quantified the levels of Gigaxonin
mRNA in the lymphoblast cell lines of GAN patients and
their relatives, as presented in Figures 1 and 2. This analysis
revealed that most of the patients present Gigaxonin
mRNA levels that are in the range of wild type Gigaxonin
mRNAs (Figure 3). Indeed, the fold changes, expressed as
the ratio of the levels of the mutated GAN mRNAs to the






Figure 2 Diminished levels of Gigaxonin corroborate with identification of mutations in the GAN locus. A Immunodetection of Gigaxonin in
new patient’s lymphoblast cell lines. (S1) and (S2) are unaffected sisters of patient F24. B Quantification of Gigaxonin in patients and their relatives,
using Tubulin or GAPDH as internal controls. Individual level of Gigaxonin is compared with the range of wild type Gigaxonin (left panel) and mutated
Gigaxonin in known GAN patients (as presented in Figure 1, right panel). The red lines correspond to the maximum individual mean value from
patients. Please note that Gigaxonin abundance was so low (undetectable) for F24 and F30 that it was detected as significantly different from mutated
Gigaxonin. N = 3-5 experiments. (T-test, *, p < 0,05; **, p < 0,01, ***, p < 0,001 and ***, p < 0,0001; error bars represent standard deviation). C Schematic
representation of Gigaxonin and the mutations identified in known patients (black) and new patients (red). D Electropherograms representing
the point mutations identified by systematic screening of the 11 exons of the GAN gene. E Illustration and F results of the CGH data, that
revealed homozygous genomic deletion encompassing exons 10 and 11 in patient F24 and heterozygosity for sister 1.
Figure 3 Nonsense mediated mRNA decay in some GAN patients. Gigaxonin mRNA levels of four control individuals (c1-4, in black), all GAN
patients (in red) and their relatives (in grey) are measured using quantitative RT-PCR with GAN-exons9-11 (A) and GAN-exons4-5 (B), and normalized
using HPRT mRNA levels. Each mRNA level is expressed as the fold change to the mean value of the four control mRNAs. (B), (F) and (M) (S1 or S2)
stand for non-affected Brother, Father, Mother, and sister, respectively N = 3 experiments. (T-test, *, p < 0,05; **, p < 0,01, ***, p < 0,001; error bars represent
standard deviation SD. A 2-fold change is statistically different).
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2, that is considered as statistically similar. Nevertheless,
four patients displayed mRNA levels that are statistically
different form the wild type mRNA levels and all of them
carry nonsense or deletion mutations in both copies of their
mRNAs (Figure 3A). Thus, the two patients F16.1 and
F16.2 displaying both a homozygous R477X mutation
present a fold change of 0,27 ± 0,12 and 0,34 ± 0,11,
respectively. Affected by another homozygous nonsense
mutation (R242X), patient F23 also has mRNA levels below
the 2 fold range (0,38 ± 0,12). The patient F18 carrying
K338X/Δ6-8 mutations displays the lowest mRNA levels
(0,04 ± 0,01). Noteworthy, when present in only on allele,
nonsense (C393X for patient F11) or deletion (Δ3-11 for
patient F25) mutation does not affect the overall stability of
Gigaxonin mRNA. Interestingly, patient F24 who carries a
homozygous deletion encompassing exons 10–11 exhibits
normal Gigaxonin mRNA level (Figure 3B). Thus, we
conclude that nonsense mediated mRNA decay is one of
the disease mechanisms leading to decreased abundance of
few GAN linked Gigaxonin but that another mechanism is
implicated.
Structural homology modeling of GAN-linked mutations
To date there is no structure of a full-length BTB-BACK-
KELCH protein, and accordingly we could not produce the
full-length Gigaxonin protein. Nonetheless, structures exist
for the BTB-BACK domain of Gigaxonin, for complexes
between other BTB-BACK domains and the N-terminal
domain of Cul3, and for KELCH domains either alone or,
in the case of Keap1, in complex with ubiquitination
substrates [17-20,23]. These structures were used as the
basis for homology modeling, to examine potential effects
of GAN disease mutations.
The existing structures of the BTB-BACK domain of
Gigaxonin and its docking to Cul3 allowed us to generate
hypotheses as to the potential effects of mutations
(Figure 4A, D). In structures of the BTB domain from Giga-
xonin, amino acid S79 caps the N-terminus of a helix from
the BTB domain, S52 and V82 form contacts internal to
the BTB domain, whereas R15 and A49 map to the homo-
dimerization interface. R138 is buried between the BACK
domain helices that form the Cul3 binding site. Thus,
mutation of any of these residues might perturb the folding
of Gigaxonin, either through altering packing of the mono-
mer or of the dimer. Mutation of R138 may also directly
impact Cul3 binding. Whereas truncation of Gigaxonin at
position R242 is expected to produce an intact BTB-BACK
fragment, we showed that the decreased abundance of
Gigaxonin is caused by activation of nonsense mediated
RNA decay in patient F23 (Figures 3, 4A, D).
The modeling suggested that L309, A324, G332, and
C464 are all buried between blades of the 6-bladed propeller
KELCH domain (Figure 4B, D). This could explain howmissense mutations in these positions would destabilize the
structure of the KELCH domain. Furthermore, all nonsense
or mutations of deletion in Gigaxonin are likely severely
destabilizing the structure, by improper folding of the β-
propeller that constitutes the KELCH domain (Figure 4C).
Non-targeted by nonsense mediated mRNA decay, the
destabilization of truncated Gigaxonin is particularly rele-
vant for the mutation C393X, deletions exons3-11 and
exon10-11. Whereas all mutations reported earlier are ex-
pected to destabilize Gigaxonin by interfering with its
homodimerization, its interaction with Cul3 or by impairing
the proper folding of either the BTB or the KELCH domain,
the mechanism of instability of Gigaxonin mutated at
residue E486 may differ. Although the modeling of loops is
less accurate due to variations in this region in KELCH
domain structures [18], this residue may be located near the
upper face of the propeller, and thus could impact protein-
protein interactions of the propeller. Notably, the corre-
sponding surface of another BTB-KELCH protein, Keap1,
interacts with ubiquitin ligase substrates through this sur-
face. Thus, one could hypothesize that impairing substrate
binding may lead to Gigaxonin instability or that the un-
stable Gigaxonin on the other allele may destabilize the het-
erodimer E486K/Δ3-11. The R269Q mutation lies outside
all regions modeled and its effect is therefore challenging to
predict.
As predicted by Gigaxonin modelization, GAN-linked
mutations exhibit shorter protein half-lives
To find out if the predicted instability of mutant Gigaxonins
could account for the decreased abundance of Gigaxonin
in patients, we determined the half-lives of wild type and
mutated Gigaxonin. Extremely challenging to assess in
patient’s cells due to the very low abundance of Gigaxonin
[8], we combined an overexpressing system in Cos cells
and a short-term incubation with 35S-methionine/cysteine
to radiolabel newly synthetized proteins and to follow
their stability over time (Figure 5). To cover the different
mechanisms of Gigaxonin instability predicted by the 3D
modelization, we selected patient’s mutations affecting the
homodimerization domain (R15S), the BTB folding and
Cul3 binding (R138H), the folding of the KELCH domain
due to single missense mutation (L309R) or massive trun-
cation (R477X). This analysis revealed a great instability of
all the mutants tested. Indeed, whereas the estimated half-
live of the wild type Gigaxonin is ≈ 10 hours, mutants ex-
hibit half-lives ranging from 1 to 3,1 hours, representing a
3,1-8,8 fold destabilization. Accordingly to the 3D model,
Gigaxonin is formed by two distinct folding structures,
the BTB and the KELCH domains that are linked together
by the BACK domain. To determine whether each domain
may affect the stability of the full-length protein or in the
contrary whether one folding unit is sufficient to promote
stability, we determined the half-lives of both the BTB-
A B
C D
Figure 4 Structural modeling of Gigaxonin and predicted destabilization due to mutations. A Structural model of the homodimer
BTB-BACK domain of Gigaxonin (purple A, B), in complex with with Cul3 (green A, B). Patient mutations lying in this domain are represented
in red. B Representation of the top and side views of a structural model for the 6-bladed β-propeller KELCH domain of Gigaxonin. Mutations
found in patients are represented in red. C Top view of the structural model for the KELCH domain of Gigaxonin, with regions deleted by the
indicated truncation mutants shown in red. D Summary of the effects predicted from the modelization of Gigaxonin for all patients included in the
study. Heterozygous mutations are represented by a thick vertical bar. Most of the mutations are predicted to destabilize Gigaxonin (red), whereas one
of them would impair substrate binding (purple). The effect of two mutations could not be determined by the 3D model (blue).
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(corresponding to the R242X mutations in F23) and C-ter
(Figure 5). This analysis showed that both fragments of
Gigaxonin are less stable than the full protein, with a 2
and a 4,2 hours half-lives for the KELCH and the BTB
domain, respectively.
Thus, altogether, the measurement of the stability of its
mutant forms provide evidence that GAN mutations confer
instability of Gigaxonin in patients, and this notion is cor-
roborated by the homology modeling of mutant locations.
Discussion
We previously identified Gigaxonin as the defective protein
in Giant Axonal Neuropathy [1]. Developing the first mo-
lecular diagnostic test for GAN by systematic sequencing of
the 11 exons of the GAN gene, we identified 23 distinct
mutations all along the gene in 22 unrelated families of
various geographic origins [1,15,24]. This diagnostic method,
complementing the clinical examination of patients is being
used worldwide by many groups and proved to be successful
in identifying most of the mutations, i.e. point mutations or
small insertions/deletions in the coding sequence as well assplice mutations near the exons-introns junctions. None-
theless, this method revealed its limitations in identifying
potential non-coding mutations (promotor, intron) or large
deletions, as revealed by our inability to detect the heterozy-
gous mutations in patients F6 and F12 [1] and the need to
use CGH array for large deletion (patient F25 [16]). Hence,
we develop and validate in this study a new diagnostic
method specific for GAN, based on the immunodetection of
Gigaxonin, that we prove to be very valuable in discriminat-
ing GAN from clinically related neuropathies.
We showed in this study that regardless of the type, the
position of the mutations or the severity of the disease, all
mutated Gigaxonins (as carried by both parental alleles)
display a drastic reduction in their abundance, reaching
85,8% in average of the normal level. The effect was so
impressive that we further assessed whether the method
may be useful for diagnostic purpose. Indeed, the first phase
of the disease progression of typical severe forms of GAN,
as well as some GAN atypical mild forms -with no involve-
ment of the central nervous system [25,26]- presents a
clinical picture closely resembling other frequent peripheral
neuropathies such as CMT2. In addition, giant axons filled
AB
Figure 5 GAN-linked Gigaxonins exhibit shorter half-lives. A Representative autoradiograms and immunoblots of the pulse chase assay for
wild type, mutant Gigaxonins, and the BTB (N-ter) and KELCH (C-ter) domains. At different times (2, 4, 6, 9, 24 h) after the beginning of the chase (0 h),
Gigaxonin was immunoprecipitated and processed for autoradiography (top panel). The signals were normalized to the tubulin immunoblotting of
the supernatent fractions of the IPs and plotted at 100% for the time point 0 h. B Half-lives of Gigaxonins. Each of the 3–4 experiments realized per
construction is plotted on the graph, to define the corresponding curve.
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logical hallmark for GAN can also been found in CMT2E
and CMT4C patients [4,5]. Thus, we collected seven new
patients with a clinical presentation and nerve biopsy
suggestive of the severe or milder form of GAN. The high
diagnostic value of our new test was validated as univocally,
all patients displaying a dramatic reduced level of Gigaxonin
were further confirmed by the identification of the corre-
sponding genetic alterations in the GAN gene. Combining
systematic sequencing to CGH analysis, we identified all
GAN mutations in 5 unrelated patients, encompassing
missense, nonsense mutations and a large deletion. Interest-
ingly, our test was able to suspect heterozygosity in a carrier
(sister S1 of patient F24) that was further confirmed by the
identification of the large GAN deletion on one allele. Note-
worthy, patients suspected to bear a mild (F29) but also a se-
vere (F28) form of GAN were excluded by our new test and
may be tested for candidate genes in autosomal recessive
forms of CMT2 or exome sequencing. Altogether, our study
reveals that the clinical evaluation of patients and the histo-
logical examination are indeed important but not sufficient
to diagnose GAN and differentiate this entity from other
frequent peripheral neuropathies. Thus, it is conceivable that
the prevalence of GAN is under-evaluated, and that our test
will be useful in identifying GAN among related CMTs.
Currently being adapted on fresh blood samples, our
methodology will enable the community to identify GANpathogenic variants from targeted diagnosis or following
high-speed sequencing analysis, and this in a cost-less and
fast manner.
Overcoming the limitation of gene sequencing, the
determination of Gigaxonin abundance has proven to be a
very important diagnostic tool -specific, reliable and robust-
in all GAN families tested so far. Nevertheless, one has to
be cautious as some mutations may confer loss of function
without necessarily conferring transcript and protein
instability. Thus, we propose to determine Gigaxonin abun-
dance prior but in concert with the systematic screening
for GAN mutations/deletions in patients, to define in the
future the confidence of our methodology as a sufficient
diagnostic test for GAN.
We previously determined that Gigaxonin is a new BTB-
KELCH protein, predominantly and equally expressed
throughout the nervous system but at very low level [8,10].
A key question in understanding how GAN-linked recessive
mutations in Gigaxonin cause the disease is to determine
how the normal protein is structured and regulated and
how patient’s mutations alter its properties. In particular, es-
tablishing whether Gigaxonin’s functions are truly mediated
by a Cul3-E3 ubiquitin ligase activity requires some know-
ledge on the stability and the 3D structure of the normal
protein. We investigated here the stability of this BTB-
KELCH protein, modelized its 3D structure and analyzed
the effect of disease-associated mutations on Gigaxonin to
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anisms in GAN. The fact that only patients carrying trun-
cated GAN gene on both alleles display a down regulation
of their mRNA would indicate a compensatory mechanism
in patients carrying compound missense and truncated
mutations: either a stabilization or a enhanced transcription
of the truncated and missense mRNA, respectively.
The homology modeling of normal Gigaxonin allowed us
to predict the structural effects of GAN mutations. Regard-
less of the stability of the mRNA levels, the majority (85%)
of the Gigaxonin mutations are predicted to map to buried
surfaces, which could alter the folding of the BTB or
KELCH domains, the homodimerization of the protein,
and/or the interaction with the Cul3 subunit of the E3
ligase. The other 15% mutations may impair substrate bind-
ing, which may indirectly still confer instability. Indeed, as
suggested for other BTB-KELCH proteins, many cullin-E3
ligase adaptors are destabilized by (auto)-ubiquitination in
the absence of substrates, possibly to avoid constitutive
activation of the E3 ligase [27]. Accordingly to this hypoth-
esis, mutations interfering with substrate binding might
activate Gigaxonin (auto) ubiquitination in patients, leading
to its degradation. With the aim to confirm instability of
mutant Gigaxonin as the key mechanism in GAN, we
demonstrated that all mutations tested, as well as isolated
BTB or KELCH structural domains, decreased the half-live
of the protein by 2 to 9 fold.
Conclusions
We have not only developed a new powerful method to
diagnose GAN, we have also provided the first evidence that
disease-associated mutations confer instability of Gigaxonin
in the human pathology. Reconstitution of the E3 ligase
activity of the Gigaxonin-Cul3 complex, together with the
identification of its partners are now essential to unravel the
mechanisms controlled by Gigaxonin in sustaining neuron
survival and cytoskeleton architecture. This will shed light
onto the role(s) of the BTB-KELCH protein Gigaxonin in
Giant Axonal Neuropathy and may contribute in the under-
standing on how mutations in the UPS contribute to neuro-
degeneration, as exemplified in Parkinson, Spinocerebellar
Ataxia, Angelman syndrome and CMT diseases.
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